Vita, G.L.; Sframeli, M.; Licata, N.; Bitto, A.; Romeo, S.; Frisone, F.; Ciranni, A.; Pallio, G.; Mannino, F.; Aguennouz, M.;
et al. A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sci. 2021, 11, 115.
https://doi.org/10.3390/brainsci11010115
AMA Style
Vita GL, Sframeli M, Licata N, Bitto A, Romeo S, Frisone F, Ciranni A, Pallio G, Mannino F, Aguennouz M,
et al. A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences. 2021; 11(1):115.
https://doi.org/10.3390/brainsci11010115
Chicago/Turabian Style
Vita, Gian Luca, Maria Sframeli, Norma Licata, Alessandra Bitto, Sara Romeo, Francesca Frisone, Annamaria Ciranni, Giovanni Pallio, Federica Mannino, M’Hammed Aguennouz,
and et al. 2021. "A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy" Brain Sciences 11, no. 1: 115.
https://doi.org/10.3390/brainsci11010115
APA Style
Vita, G. L., Sframeli, M., Licata, N., Bitto, A., Romeo, S., Frisone, F., Ciranni, A., Pallio, G., Mannino, F., Aguennouz, M., Rodolico, C., Squadrito, F., Toscano, A., Messina, S., & Vita, G.
(2021). A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences, 11(1), 115.
https://doi.org/10.3390/brainsci11010115
